Ironwood Pharmaceuticals Inc. [NASDAQ: IRWD] traded at a high on 06/02/21, posting a 1.04 gain after which it closed the day’ session at $11.68. The company report on May 27, 2021 that Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage Strength.
– The earliest licensed entry of any generic linaclotide 72 mcg, 145 mcg or 290 mcg in the U.S. is March 2029 –.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), announced that, with its partner AbbVie Inc., the companies have reached an agreement with Teva Pharmaceuticals USA, Inc. providing a license to Teva’s abbreviated new drug application (ANDA) seeking approval to market a generic version of 72 mcg LINZESS® (linaclotide) prior to the expiration of the companies’ applicable patents. With this agreement, the companies have settled with the filers of all known ANDAs to date seeking approval to market generic versions of LINZESS.
The results of the trading session contributed to over 3049207 shares changing hands. Over the past one week, the price volatility of Ironwood Pharmaceuticals Inc. stands at 2.70% while the volatility over the past one month is 3.23%.
The market cap for IRWD stock reached $1.92 billion, with 160.97 million shares outstanding and 159.99 million shares in the current float. Compared to the average trading volume of 2.07M shares, IRWD reached a trading volume of 3049207 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Ironwood Pharmaceuticals Inc. [IRWD]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for IRWD shares is $12.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on IRWD stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Wells Fargo have made an estimate for Ironwood Pharmaceuticals Inc. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on September 30, 2020. While these analysts kept the previous recommendation, Northland Capital raised their target price to Outperform. The new note on the price target was released on June 17, 2020, representing the official price target for Ironwood Pharmaceuticals Inc. stock.
The Average True Range (ATR) for Ironwood Pharmaceuticals Inc. is set at 0.35, with the Price to Sales ratio for IRWD stock in the period of the last 12 months amounting to 4.82. The Price to Book ratio for the last quarter was 17.18, with the Price to Cash per share for the same quarter was set at 2.67.
How has IRWD stock performed recently?
Ironwood Pharmaceuticals Inc. [IRWD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.01. With this latest performance, IRWD shares gained by 5.23% in over the last four-week period, additionally plugging by 1.39% over the last 6 months – not to mention a rise of 11.66% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for IRWD stock in for the last two-week period is set at 53.64, with the RSI for the last a single of trading hit 50.05, and the three-weeks RSI is set at 54.74 for Ironwood Pharmaceuticals Inc. [IRWD]. The present Moving Average for the last 50 days of trading for this stock 11.13, while it was recorded at 11.71 for the last single week of trading, and 10.71 for the last 200 days.
Ironwood Pharmaceuticals Inc. [IRWD]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Ironwood Pharmaceuticals Inc. [IRWD] shares currently have an operating margin of +40.65 and a Gross Margin at +98.28. Ironwood Pharmaceuticals Inc.’s Net Margin is presently recorded at +27.26.
Return on Total Capital for IRWD is now 37.06, given the latest momentum, and Return on Invested Capital for the company is 24.98. When it comes to the capital structure of this company, Ironwood Pharmaceuticals Inc. [IRWD] has a Total Debt to Total Equity ratio set at 724.30. Additionally, IRWD Total Debt to Total Capital is recorded at 87.87, with Total Debt to Total Assets ending up at 81.13. Long-Term Debt to Equity for the company is recorded at 719.31, with the Long-Term Debt to Total Capital now at 87.26.
Reflecting on the efficiency of the workforce at the company, Ironwood Pharmaceuticals Inc. [IRWD] managed to generate an average of $457,655 per employee. Receivables Turnover for the company is 3.25 with a Total Asset Turnover recorded at a value of 0.81.Ironwood Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 22.80.
Earnings analysis for Ironwood Pharmaceuticals Inc. [IRWD]
With the latest financial reports released by the company, Ironwood Pharmaceuticals Inc. posted 0.16/share EPS, while the average EPS was predicted by analysts to be reported at 0.09/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 77.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for IRWD.
Insider trade positions for Ironwood Pharmaceuticals Inc. [IRWD]
There are presently around $2,001 million, in the hands of institutional investors. The top three institutional holders of IRWD stocks are: WELLINGTON MANAGEMENT GROUP LLP with ownership of 21,189,305, which is approximately -1.982% of the company’s market cap and around 1.70% of the total institutional ownership; BROWN CAPITAL MANAGEMENT LLC, holding 20,170,126 shares of the stock with an approximate value of $235.59 million in IRWD stocks shares; and SARISSA CAPITAL MANAGEMENT LP, currently with $191.44 million in IRWD stock with ownership of nearly 16.738% of the company’s market capitalization.
Positions in Ironwood Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 113 institutional holders increased their position in Ironwood Pharmaceuticals Inc. [NASDAQ:IRWD] by around 17,324,895 shares. Additionally, 96 investors decreased positions by around 18,325,833 shares, while 30 investors held positions by with 135,673,367 shares. The mentioned changes placed institutional holdings at 171,324,095 shares, according to the latest SEC report filing. IRWD stock had 37 new institutional investments in for a total of 5,020,787 shares, while 30 institutional investors sold positions of 6,359,127 shares during the same period.